ELSEVIER

International Journal of Antimicrobial Agents 12 (1999) 359–361

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Author index

Volume 12 (1999)

Aarestrup, F.M., Association between the consumption of antimicrobial agents in animal husbandry and the occurrence of resistant bacteria among food animals **12**, 279
Acar, J.F., see Verhoef, J. **12**, 77
Alarcón, T., D. Domingo and M. López-Brea, Antibiotic resistance problems with *Helicobacter pylori* **12**, 19
Alarcón, T., see López-Brea, M. **12**, 33
Al-Nawas, B., see Wahlmann, U. **12**, 253
Alou, L., M.L. Anta, M.G. Del Potro, F. Fuentes, I.P. Balcabao, M.L. Gomez-Lus and J. Prieto, Efficacy of trovafloxacin in an in vitro pharmacodynamic simulation of an intraabdominal infection **12**, 135
Anta, M.L., see Alou, L. **12**, 135
Antunes, F., see Grüneberg, R.N. **12**, 191
Aplasca, M.-R., see Trees, D.L. **12**, 325
Araj, G.F., H.A. Bey, L.Y. Itani and S.S. Kanj, Drug-resistant *Streptococcus pneumoniae* in the Lebanon: implications for presumptive therapy **12**, 349
Arora, D.S. and J. Kaur, Antimicrobial activity of spices **12**, 257
Azzarelli, C., see Puntorieri, M. **12**, 333

Balcabao, I.P., see Alou, L. **12**, 135
Balzarini, J., see Smeijsters, L.J.J.W. **12**, 53
Barbadora, K., see Kearney, J.A. **12**, 141
Barette, S., see van Agtmael, M. **12**, 159
Bergan, T., see Stray-Pedersen, B. **12**, 245
Bernard, J., see van Agtmael, M. **12**, 159
Bey, H.A., see Araj, G.F. **12**, 349
Bjarnason, J., see Blondeau, J.M. **12**, 67
Blondeau, J.M. and G.S. Tillotson, Formula to help select rational antimicrobial therapy (FRAT): its application to community- and hospital-acquired urinary tract infections **12**, 145
Blondeau, J.M., D. Church, Y. Yaschuk and J. Bjarnason, In vitro activity of several antimicrobial agents against 1003 isolates of *Streptococcus pyogenes* collected from Western Canada **12**, 67
Bonfiglio, G., see Puntorieri, M. **12**, 333
Bouchaud, O., see van Agtmael, M. **12**, 159
Bow, L., see Onyeji, C.O. **12**, 301
Bui, K.Q., see Onyeji, C.O. **12**, 301
Bui, K.Q., see Onyeji, C.O. **12**, 107
Bun Leng, H., see Trees, D.L. **12**, 325
Bunnik, M.C.M., see de Klerk, G.J. **12**, 121

Cafiso, V., see Puntorieri, M. **12**, 333
Carbone, M., M.T. Fera, M.G. Pennisi, M. Masucci, A. De Sarro and C. Macrì, Activity of nine fluoroquinolones against strains of *Bordetella bronchiseptica* **12**, 355
Catalano, V., see Puntorieri, M. **12**, 333
Chambers, H.F., see Grüneberg, R.N. **12**, 191
Chandrasekar, P.H., see Manavathu, E.K. **12**, 213
Cheng-Qi, S., see van Agtmael, M.A. **12**, 151
Chiu, C.-H., T.-Y. Lin and J.T. Ou, In vitro evaluation of intracellular activity of antibiotics against non-typhoid *Salmonella* **12**, 47
Church, D., see Blondeau, J.M. **12**, 67
Coto, C.E., see Wachsman, M.B. **12**, 293
Cristino, J.M., Correlation between consumption of antimicrobials in humans and development of resistance in bacteria **12**, 199

Danis, M., see van Agtmael, M. **12**, 159
De Clercq, E., Perspectives for the treatment of hepatitis B virus infections **12**, 81
de Clercq, E., see Smeijsters, L.J.J.W. **12**, 53
de Klerk, G.J., J.H.M. van Steijn, S. Lobatto, C.A.J.J. Jaspers, W.C.J. van Veldhuizen, C.A.J. Hensing, M.C.M. Bunnik, W.H. Geraedts, A.S.M. Dofferhof, J. Van Den Berg, J.H.J.M. Melis and A.I.M. Hoepelman, A randomised, multicentre study of ceftriaxone versus standard therapy in the treatment of lower respiratory tract infections **12**, 121
de las Cuevas, C., see López-Brea, M. **12**, 33
Delmont, J., see van Agtmael, M. **12**, 159
Del Potro, M.G., see Alou, L. **12**, 135
Denning, D.W., see Oakley, K.L. **12**, 267
de Ruiz Holgado, A.P., see Wachsman, M.B. **12**, 293
De Sarro, A., F. Naccari and G. De Sarro, Enhanced susceptibility of pentylenetetrazole kindled mice to quinolone effects **12**, 239
De Sarro, A., see Carbone, M. **12**, 355
De Sarro, G., see De Sarro, A. **12**, 239
de Torres, R.A., see Wachsman, M.B. **12**, 293
de Vries, E., see Smeijsters, L.J.J.W. **12**, 53
Dhople, A.M., In vitro activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with brodimoprim and dapsone, against *Mycobacterium leprae* **12**, 319
Diarra, M.S., F. Malouin and M. Jacques, Postantibiotic and physiological effects of tilmicosin, tylosin, and apramycin at subminimal and suprainhibitory concentrations on some swine and bovine respiratory tract pathogens **12**, 229
Dofferhof, A.S.M., see de Klerk, G.J. **12**, 121
Domingo, D., see Alarcón, T. **12**, 19
Domingo, D., see López-Brea, M. **12**, 33
Donnelly, J.P., Commentary on the MAFF technical report: a review of antimicrobial resistance in the food chain **12**, 63
Drago, L., see Gismondo, M.R. **12**, 287
Duc-Dao, L., see Masimirembwa, C.M. **12**, 203

Eick, S., W. Pfister and E. Straube, Antimicrobial susceptibility of anaerobic and capnophilic bacteria isolated from odontogenic abscesses and rapidly progressive periodontitis **12**, 41

PII: S0924-8579(98)00106-5

Farías, M.E., see Wachsman, M.B. **12**, 293
Fera, M.T., see Carbone, M. **12**, 355
Finch, R.G., A review of worldwide experience with sparfloxacin in the treatment of community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis **12**, 5
Fluit, A.C., see Schmitz, F.-J. **12**, 311
Franssen, F.F.J., see Smeijsters, L.J.J.W. **12**, 53
Fresnadillo, M.J., see Trujillano-Martín, I. **12**, 185
Fuentes, F., see Alou, L. **12**, 135

Gage, A., see Minassian, M.A. **12**, 263
Garau, J., see Grüneberg, R.N. **12**, 191
García-Rodríguez, J.Á., see Trujillano-Martín, I. **12**, 185
García-Sánchez, E., see Trujillano-Martín, I. **12**, 185
García-Sánchez, J.E., see Trujillano-Martín, I. **12**, 185
Gathmann, I., see van Agtmael, M. **12**, 159
Geraedts, W.H., see de Klerk, G.J. **12**, 121
Gismondo, M.R., L. Drago and A. Lombardi, Review of probiotics available to modify gastrointestinal flora **12**, 287
Giuseppe, N., see Puntorieri, M. **12**, 333
Gomez-Lus, M.L., see Alou, L. **12**, 135
Goto, Y., see Niwano, Y. **12**, 221
Graham, D.Y., see Osato, M.S. **12**, 341
Graninger, W., see Grüneberg, R.N. **12**, 191
Gras, C., see van Agtmael, M. **12**, 159
Green, M., see Kearney, J.A. **12**, 141
Grøgaard, J., see Stray-Pedersen, B. **12**, 245
Gross, G., Do we need antivirals for genital herpes simplex virus and human papillomavirus infection? **12**, 1
Grüneberg, R.N., F. Antunes, H.F. Chambers, J. Garau, W. Graninger, F. Menichetti, W.E. Peetermans, D. Pittet, P.M. Shah and D. Vogelaers, The role of glycopeptide antibiotics in the treatment of infective endocarditis **12**, 191
Gupta, R., see Verhoef, J. **12**, 77

Hafstad, A., see Stray-Pedersen, B. **12**, 245
Hammerschlag, M.R., see Roblin, P.M. **12**, 181
Hensing, C.A.J., see de Klerk, G.J. **12**, 121
Hoepelman, A.I.M., see de Klerk, G.J. **12**, 121
Holý, A., see Smeijsters, L.J.J.W. **12**, 53

Itani, L.Y., see Araj, G.F. **12**, 349

Jacques, M., see Diarra, M.S. **12**, 229
Jaspers, C.A.J.J., see de Klerk, G.J. **12**, 121
Jensen, T.G., H.J. Kolmos and K. Siboni, Resistance problems in two university hospitals in Denmark **12**, 71
Jones, R., see Verhoef, J. **12**, 77
Jütte, M., see Wahlmann, U. **12**, 253

Kanai, K., see Niwano, Y. **12**, 221
Kanj, S.S., see Araj, G.F. **12**, 349
Kantzanou, M., P.T. Tassios, A. Tseleni-Kotsovili, A.N. Maniatis, A.C. Vatopoulos and N.J. Legakis, A multi-centre study of nosocomial methicillin-resistant *Staphylococcus aureus* in Greece **12**, 115
Kaur, J., see Arora, D.S. **12**, 257
Kearney, J.A., K. Barbadora, E.O. Mason, E.R. Wald and M. Green, In vitro activities of the oxazolidinone compounds linezolid (PNU-100766) and eperzolid (PNU-100592) against middle ear isolates of *Streptococcus pneumoniae* **12**, 141
Knapp, J.S., see Trees, D.L. **12**, 325
Kodama, H., see Niwano, Y. **12**, 221
Kolmos, H.J., see Jensen, T.G. **12**, 71
Kutlin, A., see Roblin, P.M. **12**, 181
Kuzuhara, N., see Niwano, Y. **12**, 221

Legakis, N.J., see Kantzanou, M. **12**, 115
Lin, T.-Y., see Chiu, C.-H. **12**, 47
Lobatto, S., see de Klerk, G.J. **12**, 121
Lombardi, A., see Gismondo, M.R. **12**, 287
López-Brea, M., N. Prieto, D. Domingo, C. de las Cuevas, I. Sánchez and T. Alarcón, In vitro activity of clinafloxacin against fluoroquinolone resistant Spanish clinical isolates **12**, 33
López-Brea, M., see Alarcón, T. **12**, 19

Macrì, C., see Carbone, M. **12**, 355
Malouin, F., see Diarra, M.S. **12**, 229
Malvy, D., see van Agtmael, M. **12**, 159
Manavathu, E.K., J.A. Vazquez and P.H. Chandrasekar, Reduced susceptibility in laboratory-selected mutants of *Aspergillus fumigatus* to itraconazole due to decreased intracellular accumulation of the antifungal agent **12**, 213
Maniatis, A.N., see Kantzanou, M. **12**, 115
Masimirembwa, C.M., N. Phuong-dung, B.Q. Phuc, L. Duc-Dao, N.D. Sy, O. Sköld and G. Swedberg, Molecular epidemiology of *Plasmodium falciparum* antifolate resistance in Vietnam: genotyping for resistance variants of dihydropteroate synthase and dihydrofolate reductase **12**, 203
Maskell, J.P., see Sefton, A.M. **12**, 129
Mason, E.O., see Kearney, J.A. **12**, 141
Masucci, M., see Carbone, M. **12**, 355
Mazzei, T., see Periti, P. **12**, 97
Melis, J.H.J.M., see de Klerk, G.J. **12**, 121
Menichetti, F., see Grüneberg, R.N. **12**, 191
Messina, C., see Puntorieri, M. **12**, 333
Minassian, M.A., A. Gage, E. Price and A.M. Sefton, Imipenem for the treatment of melioidosis **12**, 263
Miyazaki, T., see Niwano, Y. **12**, 221
Montes Martínez, I., see Trujillano-Martín, I. **12**, 185
Moore, C.B., see Oakley, K.L. **12**, 267
Mull, R., see van Agtmael, M. **12**, 159
Mull, R., see van Agtmael, M.A. **12**, 151
Munechika, Y., see Niwano, Y. **12**, 221

Naccari, F., see De Sarro, A. **12**, 239
Naesens, L., see Smeijsters, L.J.J.W. **12**, 53
Nicolau, D.P., see Onyeji, C.O. **12**, 301
Nicolau, D.P., see Onyeji, C.O. **12**, 107
Nightingale, C.H., see Onyeji, C.O. **12**, 301
Nightingale, C.H., see Onyeji, C.O. **12**, 107
Niwano, Y., N. Kuzuhara, Y. Goto, Y. Munechika, H. Kodama, K. Kanai, M. Yoshida, T. Miyazaki and H. Yamaguchi, Efficacy of NND-502, a novel imidazole antimycotic agent, in experimental models of *Candida albicans* and *Aspergillus fumigatus* infections **12**, 221
Normann, E., see Stray-Pedersen, B. **12**, 245

Oakley, K.L., C.B. Moore and D.W. Denning, Activity of pradimicin BMS-181184 against *Aspergillus* spp **12**, 267
Onyeji, C.O., K.Q. Bui, D.P. Nicolau, C.H. Nightingale, L. Bow and R. Quintiliani, Influence of adjunctive interferon-γ on treatment of gentamicin- and vancomycin-resistant *Enterococcus faecalis* infection in mice **12**, 301
Onyeji, C.O., K.Q. Bui, R.C. Owens, Jr., D.P. Nicolau, R. Quintiliani and C.H. Nightingale, Comparative efficacies of levofloxacin and ciprofloxacin against *Streptococcus pneumoniae* in a mouse model of experimental septicaemia **12**, 107
Osato, M.S., R. Reddy and D.Y. Graham, Metronidazole and clarithromycin resistance amongst *Helicobacter pylori* isolates from a large metropolitan hospital in the United States **12**, 341
Ou, J.T., see Chiu, C.-H. **12**, 47
Overdulve, J.P., see Smeijsters, L.J.J.W. **12**, 53
Owens, R.C., Jr., see Onyeji, C.O. **12**, 107

Peetermans, W.E., see Grüneberg, R.N. **12**, 191
Pennisi, M.G., see Carbone, M. **12**, 355
Periti, P. and T. Mazzei, New criteria for selecting the proper antimicrobial chemotherapy for severe sepsis and septic shock **12**, 97
Peto-Mesola, V., see Trees, D.L. **12**, 325
Pfister, W., see Eick, S. **12**, 41
Phuc, B.Q., see Masimirembwa, C.M. **12**, 203
Phuong-dung, N., see Masimirembwa, C.M. **12**, 203
Pittet, D., see Grüneberg, R.N. **12**, 191
Price, E., see Minassian, M.A. **12**, 263
Prieto, J., see Alou, L. **12**, 135
Prieto, N., see López-Brea, M. **12**, 33
Puntorieri, M., V. Cafiso, M. Santagati, C. Messina, C. Azzarelli, V. Catalano, G. Bonfiglio, N. Giuseppe and S. Stefania, In vitro selection of glycopeptide-resistant variants of Enterococci **12**, 333

Qing, J.X., see van Agtmael, M.A. **12**, 151
Quintiliani, R., see Onyeji, C.O. **12**, 301
Quintiliani, R., see Onyeji, C.O. **12**, 107

Ravaoarinoro, M. and C. Therrien, β-Lactamases and outer membrane investigations in β-lactam-resistant *Comamonas acidovorans* strains **12**, 27
Reddy, R., see Osato, M.S. **12**, 341
Reznik, T., see Roblin, P.M. **12**, 181
Roblin, P.M., A. Kutlin, T. Reznik and M.R. Hammerschlag, Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of *Chlamydia pneumoniae* **12**, 181

Sánchez, I., see López-Brea, M. **12**, 33
Sandul, A.L., see Trees, D.L. **12**, 325
Santagati, M., see Puntorieri, M. **12**, 333
Schmitz, F.-J., J. Verhoef and A.C. Fluit, Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme **12**, 311
Sefton, A.M., J.P. Maskell and J.D. Williams, Selection of resistant variants of respiratory pathogens by quinolones **12**, 129
Sefton, A.M., see Minassian, M.A. **12**, 263
Sesma, F., see Wachsman, M.B. **12**, 293
Shah, P.M., see Grüneberg, R.N. **12**, 191
Shryock, T.R., Relationship between usage of antibiotics in food-producing animals and the appearance of antibiotic resistant bacteria **12**, 275
Siboni, K., see Jensen, T.G. **12**, 71
Sköld, O., see Masimirembwa, C.M. **12**, 203
Smeijsters, L.J.J.W., F.F.J. Franssen, L. Naesens, E. de Vries, A. Holý, J. Balzarini, E. de Clercq and J.P. Overdulve, Inhibition of the in vitro growth of *Plasmodium falciparum* by acyclic nucleoside phosphonates **12**, 53
Stefania, S., see Puntorieri, M. **12**, 333
Straube, E., see Eick, S. **12**, 41
Stray-Pedersen, B., T. Bergan, A. Hafstad, E. Normann, J. Grøgaard and M. Vangdal, Vaginal disinfection with chlorhexidine during childbirth **12**, 245
Swedberg, G., see Masimirembwa, C.M. **12**, 203
Sy, N.D., see Masimirembwa, C.M. **12**, 203

Takeda, E., see Wachsman, M.B. **12**, 293
Tassios, P.T., see Kantzanou, M. **12**, 115
Therrien, C., see Ravaoarinoro, M. **12**, 27
Tillotson, G.S., see Blondeau, J.M. **12**, 145
Touze, J.-E., see van Agtmael, M. **12**, 159
Trees, D.L., A.L. Sandul, V. Peto-Mesola, M.-R. Aplasca, H. Bun Leng, W.L. Whittington and J.S. Knapp, Alterations within the quinolone resistance-determining regions of GyrA and ParC of *Neisseria gonorrhoeae* isolated in the Far East and the United States **12**, 325
Trujillano-Martín, I., E. García-Sánchez, M.J. Fresnadillo, J.E. García-Sánchez, J.Á. García-Rodríguez and I. Montes Martínez, In vitro activities of five new antimicrobial agents against *Brucella melitensis* **12**, 185
Tseleni-Kotsovili, A., see Kantzanou, M. **12**, 115

van Agtmael, M.A., S. Cheng-Qi, J.X. Qing, R. Mull and C.J. van Boxtel, Multiple dose pharmacokinetics of artemether in Chinese patients with uncomplicated falciparum malaria **12**, 151
van Agtmael, M., O. Bouchaud, D. Malvy, J. Delmont, M. Danis, S. Barette, C. Gras, J. Bernard, J.-E. Touze, I. Gathmann and R. Mull, The comparative efficacy and tolerability of CGP 56697 (artemether + lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France **12**, 159
van Boxtel, C.J., see van Agtmael, M.A. **12**, 151
Van Den Berg, J., see de Klerk, G.J. **12**, 121
Vangdal, M., see Stray-Pedersen, B. **12**, 245
van Steijn, J.H.M., see de Klerk, G.J. **12**, 121
van Veldhuizen, W.C.J., see de Klerk, G.J. **12**, 121
Vatopoulos, A.C., see Kantzanou, M. **12**, 115
Vazquez, J.A., see Manavathu, E.K. **12**, 213
Verhoef, J., J.F. Acar, R. Gupta and R. Jones, Surveillance of resistance against antimicrobial agents **12**, 77
Verhoef, J., see Schmitz, F.-J. **12**, 311
Vogelaers, D., see Grüneberg, R.N. **12**, 191

Wachsman, M.B., M.E. Farías, E. Takeda, F. Sesma, A.P. de Ruiz Holgado, R.A. de Torres and C.E. Coto, Antiviral activity of enterocin CRL35 against herpesviruses **12**, 293
Wagner, W., see Wahlmann, U. **12**, 253
Wahlmann, U., B. Al-Nawas, M. Jütte and W. Wagner, Clinical and microbiological efficacy of single dose cefuroxime prophylaxis for dental surgical procedures **12**, 253
Wald, E.R., see Kearney, J.A. **12**, 141
Whittington, W.L., see Trees, D.L. **12**, 325
Williams, J.D., see Sefton, A.M. **12**, 129
Williams, J.D., The WHO model list of essential drugs **12**, 171

Yamaguchi, H., see Niwano, Y. **12**, 221
Yaschuk, Y., see Blondeau, J.M. **12**, 67
Yoshida, M., see Niwano, Y. **12**, 221